A Systematic Review of Palpitations Prevalence by Menopausal Status

About 21 million women living in the USA today and 1.1 billion women worldwide by 2025 will experience menopausal symptoms [1‐5], which begin when menses become irregular or stop [1, 6]. Menopausal symptoms can last for 10 to 15 years [1, 6]. Women’s symptoms vary [7] with > 75% of women reporting vasomotor symptoms (hot flashes, night sweats) [1] that sometimes occur with palpitations [8, 9]. Although hot flashes are a frequently researched symptom with evidence-based effective hormonal and non-hormonal treatments, less is known about perimenopausal and postmenopausal palpitations.

Palpitations are described by women as missed, irregular, or exaggerated heart beats [10•, 11]. In research, the symptom is assessed by a variety of methods including standard menopausal symptom assessment tools. As examples, on the 11-item Menopause Rating Scale, women are asked about “heart discomfort (unusual awareness of heart beat, heart skipping, heart racing, or tightness)” [12•], and on the Kupperman Index, women are asked about “palpitations” [13]. Despite the widespread use of these and other similar assessment tools, no published reviews synthesize findings on palpitations across studies of menopausal women. In particular, the lack of published information regarding the prevalence of palpitations interferes with understanding the scope of the problem at a population level. Without that information, it is difficult to determine whether this is a menopausal symptom that warrants attention, such as electrocardiogram monitoring. To address this gap in the literature, the purpose of this review was to integrate quantitative evidence on the prevalence of palpitations by menopausal status.

This was a systematic review of studies reporting rates of palpitations by menopausal status that followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Figure 1 shows the disposition of the articles at screening and review levels. At the title/abstract stage, 62 of the 670 articles (9.25%) were deemed irrelevant and excluded. The main reasons were no palpitation information in the title or abstract, not data based (e.g., reviews, protocols, case studies), and animal studies. This resulted in 608 articles for full text review. At full-text review, 603 articles were excluded with the three most common reasons being no palpitations data reported, reported palpitations prevalence but not in relation to menopausal status, or unspecified measurement recall periods and/or response options. A total of 5 articles were retained for the review [26••, 27‐30].

Table 1 contains descriptions of the articles. All contained findings from cross-sectional menopausal symptom surveys published between 1974 and 2010. Countries included Bangladesh, Malaysia, Nigeria, the UK, and the USA. Three samples were community based, and two did not specify whether samples which were recruited from health centers represented the community. Sample age ranges varied, and all articles included premenopausal, perimenopausal, and postmenopausal women. Total sample sizes ranged from 356 to 12,425 women.

Two studies were good quality and low bias (see Table 1). Gold et al. contained lack of clarity on the number of women eligible and approached [26••]. Olaolorun et al. lacked clarity on whether the full item from a standardized questionnaire was used [28]. Three studies were fair quality and moderate bias (see Table 1). McKinlay included a subset of the original study, a long recall period of 1 year for surveys, and lack of clarity on standardization of measurement procedures [27]. Rahman’s 2010 and 2011 articles were fair quality with moderate bias due to lack of clarity on representativeness of the target population, lack of information on response rates and attrition, and lack of clarity on whether the full item from a standardized questionnaire was used [29, 30].

Table 2 shows the measurement tool name, item, recall period, and response options. All studies used single items to assess palpitations as present [26••, 27‐29, 31], and one additionally assessed severity [28]. Translation and linguistic validation were not mentioned in one article [26••]. Three studies used the Menopause Rating Scale or a modified version of it though none of these articles referenced the full item stem [28‐30]. Recall periods included 2 weeks [26••], a month [28‐30], and a year [27].

Table 2 also shows prevalence by menopausal status. Overall prevalence rates were reported but are not useful for understanding palpitations as a menopause transition-varying symptom. Rates for premenopausal women varied 10-fold from 3.7% (Malaysia) [30] to 40.2% [27]. Prevalence rates for perimenopausal women varied 2-fold from 20.1% (USA early perimenopausal) or 20.7% (USA late perimenopausal) [26••] to 42.0% (Nigeria) [28]. Rates for postmenopausal women varied from 15.7% (Bangladesh) [29] to 54.1% (UK) [27]. Across all articles, palpitation prevalence rates in perimenopausal women tended to be higher than premenopausal and/or postmenopausal women. Statistical tests of differences in palpitation prevalence by menopausal status reported in the articles confirmed that observation. In three of five articles, compared with premenopausal and postmenopausal women, palpitation prevalence was significantly higher among perimenopausal and/or surgically postmenopausal women [26••, 29, 30].

To the best of our knowledge, this is the first review to focus on the prevalence of menopausal palpitations. This review was a first step in understanding palpitations in perimenopausal and postmenopausal women in order to determine whether this symptom requires addition follow-up, such as electrocardiogram monitoring to assess whether menopausal palpitations are associated with clinically important arrhythmias or electrocardiogram changes. This review suggests that palpitations are prevalent at a rate indicating that they warrant further attention from clinicians and researchers.

There are several important findings that will be relevant to researchers and/or clinicians. First, there are a limited number of studies overall (n = 5) and a smaller number of good-quality studies (n = 2) providing evidence on the prevalence of palpitations by menopausal stage around the world. The lack of evidence is particularly noteworthy in comparison with other well-studied menopausal symptoms, like vasomotor symptoms (e.g., hot flashes and night sweats) which result in search yields of over 17,000 articles. The few articles that were available for this review indicate that palpitations may affect nearly one of every five or more perimenopausal and/or postmenopausal women. Although differences across studies in measurement recall periods make it difficult to directly compare findings by country, palpitations were prevalent in women living in 5 different countries representing 4 continents.

Second, the higher prevalence of palpitations among perimenopausal and surgically postmenopausal women suggests that physiological changes of menopause may play a role in the development or presence of palpitations. Dennerstein et al. showed that certain menopausal symptoms were triggered by rapidly declining estrogen rather than absolute estrogen levels per se [6]. In that study, a sharper slope of change in estrogen over the menopause transition was linked to symptoms, explaining some of the intra-individual differences in menopausal symptom experiences that have been widely documented. However, the symptom assessment in that study included only four symptoms: hot flashes, night sweats, vaginal dryness, and trouble sleeping. Palpitations were not assessed but may also be related to slope of estrogen change since studies showed prevalence vary by menopausal stage.

Third, this review suggests a need to standardize the assessment of menopausal palpitations. Having clinical practitioners and menopausal women contribute their thoughts on what phrases would be best to capture the symptom could generate relevant items for future psychometric testing by researchers. In the articles reviewed, items assessing the feeling of palpitations (heart pounding or racing) may invoke different responses than the item heart discomfort, which could evoke angina-like symptoms. Standardizing recall periods would also be helpful. It is difficult to compare findings across articles where recall periods varied from more acute to more chronic time periods (e.g., 2–4 weeks vs. 1 year). Further research is needed to identify the optimal recall period. Finally, although the validated Menopause Rating Scale was used in three studies, there were variations in the administration mode, item wording, and response options. Our review findings suggest that there may be a need for a common assessment methodology to compare findings more easily across studies.

There were several strengths and some limitations to this review. In terms of strengths, this review provides a first-time summary of prevalence of palpitations by menopausal stage. The search terms and processes for searching, screening, reviewing, and abstracting were systematically and rigorously conducted. During the screening phase, we erred on being overly inclusive so as not to eliminate potentially relevant articles. Limitations include the fact that the search was limited to English language articles. It is possible that relevant studies published in other languages were omitted. In addition, the articles resulting from the search were limited in number and most had methodological limitations as reflected in the quality and bias ratings.

In conclusion, this review suggests that menopausal palpitations affect at least one in five perimenopausal and postmenopausal women, suggesting that the symptom is worthy of attention in clinical practice and research. To advance the field, it will be important to standardize how this symptom is assessed in relation to menopausal status. Use of similar phrases, recall periods, and response options will help generate more standardized data across practice and research settings to facilitate evidence synthesis and comparisons across studies and populations.